Health TrialsbyHealthPanel

Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients

ConditionChronic Cough
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-70
SponsorImperial College London

About this trial

This study is being done in order to understand what causes people to have a chronic cough, which is defined as a cough lasting for more than 8 weeks. The research team wish to find out whether there is any inflammation in the lungs of patients with chronic cough. The research team will also determine whether a suspected chemical produced in the body, called adenosine triphosphate (ATP) can be responsible for causing the chronic cough. In order to be able to find out what is abnormal in those who have a chronic cough, The research team will need to compare their results with those that do not have a chronic cough.

In this study, the research team will examine 10 participants who suffer from chronic cough and 8 individuals who do not have a chronic cough and are healthy.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Patients who suffer from chronic cough and healthy volunteers

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

18 Participants
are grouped into 2 trial groups
Group A: Chronic Cough
Group B: Healthy

Trial outcomes

Primary outcomes

1

Presence of ATP in airways of idiopathic chronic cough patients and the localisation of P2X2/3 receptors in the airways

Measure ATP concentrations in exhaled breath condensate and use immunohistochemistry to identify P2X2/3 receptors in lung endobronchial biopsies.

Time frame
18 months
2

Cough sensitivity and laryngeal sensitivity to exogenous ATP

Count the number of cough in response to capsaicin pre and post ATP exposure

Time frame
18 months
3

Examine the effects of exogenous ATP on the inflammatory response in the upper and lower airways.

Count the number of immune cells in sputum and BALF pre and post ATP by microscopy

Time frame
18 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Imperial College London

Lead sponsor

Merck Sharp & Dohme LLC

Collaborator

Source ClinicalTrials.gov
Apply now